NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated FDA Pathway Potential
Beam Therapeutics (BEAM) is back in focus after new clinical data for its BEAM-302 program showed sustained protective protein levels. This supports an accelerated FDA review path and helps to reset investor attention on the stock.
See our latest analysis for Beam Therapeutics.
The fresh BEAM-302 data arrives after a sharp pullback, with a 1-day share price return of down 10.47% and a 7-day share price return of down 10.72%. However, the 1-year total shareholder return of 58.28% contrasts...